Brief: Valbiotis Initiates The Clinical Development Of Valediatm In The United-States With The Reverse-It Clinical Study
15/05/2018 17:21
Valbiotis SAS ALVAL.PA :
* VALBIOTIS INITIATES THE CLINICAL DEVELOPMENT OF VALEDIATM
IN THE
UNITED-STATES WITH THE REVERSE-IT CLINICAL STUDY
Source text for Eikon: ID:nBwBcK9Na
Further company coverage: ALVAL.PA
Recent news on Valbiotis SA
See all newsBrief: Valbiotis Announces Creation By Chinese JV Of Subsidiary In Singapore
French and Benelux stocks-Factors to watch
Brief: Valbiotis FY Operating Profit Eur -9.5 Mln
Brief: Valbiotis Launches Capital Increase For Gross Amount Of Nearly EUR 6.9 Mln
Brief: Valbiotis Signs Strategic Agreements With Two Pharmaceutical Groups